Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure (PHOENIX)
A Prospective, Multicenter, Randomized Controlled Trial of HAHD With pHA130 Cartridge vs. Conventional High-Flux HD for Clearance of Protein-Bound Uremic Toxins and Quality of Life Improvement in Kidney Failure.
Patients on maintenance hemodialysis (MHD) face a high risk of cardiovascular mortality and reduced quality of life. Conventional high-flux hemodialysis (HD) is the standard of care but has limited efficacy in clearing middle-molecular and protein-bound uremic toxins (PBUTs). The accumulation of these toxins is associated with adverse long-term outcomes.
This study evaluates the efficacy and safety of the pHA130 hemoadsorption cartridge, which utilizes a modified resin for enhanced PBUT adsorption, when combined with hemodialysis (HAHD). This is a prospective, open-label, multi-center, randomized controlled trial involving 100 MHD patients. Participants will be randomized 1:1 to either the HAHD group (receiving one HAHD session using the pHA130 cartridge and two standard HD sessions weekly) or the Control group (receiving three standard HD sessions weekly).
The primary objective is to assess the reduction in serum indoxyl sulfate (IS) and p-cresol sulfate (PCS) levels from baseline to 12 months. Secondary objectives include evaluating changes in quality of life (KDQoL-SF, MMSE), the progression of coronary artery calcification (CAC), the incidence of major adverse cardiovascular events (MACEs), all-cause mortality, and safety profiles. This trial aims to determine if integrating long-term HAHD therapy can optimize blood purification strategies for the MHD population.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Patients with chronic kidney disease (CKD), particularly those on maintenance hemodialysis (MHD), face a high burden of cardiovascular disease and significantly impaired health-related quality of life. Traditional hemodialysis (HD) and hemodiafiltration (HDF) are effective at clearing small water-soluble molecules, but their efficacy in removing protein-bound uremic toxins (PBUTs)-such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS)-is notably limited. The accumulation of PBUTs is strongly associated with vascular calcification, increased cardiovascular mortality, and severe symptoms like uremic pruritus.
Hemoadsorption combined with hemodialysis (HAHD) has emerged as a promising strategy to address this gap. The novel pHA130 hemoadsorption cartridge features a modified resin with micro-controlled positive charges, enhancing its targeted adsorption capacity for PBUTs through electrostatic, hydrophobic, and molecular sieving mechanisms. In vitro studies have shown IS and PCS clearance rates exceeding 90%.
The PHOENIX trial is a prospective, open-label, multicenter, randomized controlled trial designed to evaluate the long-term clinical efficacy and safety of the pHA130 cartridge in MHD patients. Following a 4-week run-in period, eligible participants will be randomized 1:1 into two arms:
Experimental Group (HAHD): Receives high-flux HD twice a week and HAHD once a week. During HAHD, the pHA130 cartridge is placed in series before the high-flux dialyzer.
Control Group (HD): Receives conventional high-flux HD three times a week.
The primary endpoint is the percentage reduction in serum IS and PCS concentrations from baseline to 12 months. Secondary endpoints include changes in health-related quality of life (assessed by KDQoL-SF) and cognitive function (assessed by MMSE), progression of coronary artery calcification (CAC) measured by Agatston score, incidence of major adverse cardiovascular events (MACEs), all-cause mortality, and safety metrics. The results of this study aim to provide robust evidence for optimizing blood purification strategies and improving long-term outcomes for patients with end-stage renal disease.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jian Lu, PhD
- Número de teléfono: +8619834515101
- Correo electrónico: lujiandr@163.com
Copia de seguridad de contactos de estudio
- Nombre: Shimin Jiang, PhD
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age > 18 years.
- On maintenance hemodialysis for > 3 months.
- Receiving hemodialysis 3 times per week, 4 hours per session.
- Standard Kt/V ≥ 1.2.
- Voluntarily participates and provides written informed consent.
Exclusion Criteria:
- Known allergy to the dialyzer or hemoperfusion device.
- Platelet count < 60×10⁹/L.
- Serum albumin < 30 g/L.
- 24-hour urine output > 200 ml.
- Inability to achieve a blood flow rate ≥ 200 ml/min.
- Coagulation disorders, severe bleeding tendency, or active bleeding.
- Pre-dialysis systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg.
- Active malignancy.
- Active infection, or severe, critical illness of cardiac, pulmonary, hepatic, or nervous systems.
- Planned living-donor kidney transplant within the next 6 months.
- Current participation in another interventional clinical study, or participation within the past 3 months in an interventional study that may interfere with the present study (e.g., fecal microbiota transplantation); or use of intestinal microecological regulators such as probiotics.
- History of unstable angina, myocardial infarction, malignant arrhythmia, cardiac or peripheral vascular surgery, or cerebrovascular accident within the past 8 weeks.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: HAHD Group
Participants assigned to this group will receive a combination of hemodialysis (HD) and hemoadsorption (HA) therapy.
|
Following a 4-week run-in period,patients receive High-flux hemodialysis (HD) twice a week and combined HAHD once a week.
During the HAHD session, the pHA130 hemoadsorption cartridge is placed in series with a high-flux dialyzer.
Each treatment session lasts for 4 hours.
|
|
Comparador activo: HD Group
Participants assigned to this group will receive standard maintenance hemodialysis therapy.
|
Patients receive conventional high-flux hemodialysis (HD) three times a week.
Each treatment session lasts for 4 hours.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Reduction Ratio from baseline in Serum Indoxyl Sulfate (IS) and p-Cresol Sulfate (PCS) Concentration
Periodo de tiempo: Baseline, 3, 6, 9, 12 Months
|
Percentage reduction in serum IS and PCS concentration from baseline after 12 months of treatment, measured by High-Performance Liquid Chromatography (HPLC).
|
Baseline, 3, 6, 9, 12 Months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in Health-Related Quality of Life (HRQoL)
Periodo de tiempo: Baseline, 3, 6, 9, 12 Months
|
Health-Related Quality of Life (HRQoL) is assessed using the Kidney Disease Quality of Life Short Form (KDQOL-SF).
The KDQOL-SF scores range from a minimum of 0 to a maximum of 100.
A higher score indicates a better health-related quality of life.
|
Baseline, 3, 6, 9, 12 Months
|
|
Change from baseline in Cognitive Function
Periodo de tiempo: Baseline, 3, 6, 9, 12 Months
|
Cognitive function is assessed using the Mini-Mental State Examination (MMSE).
The MMSE total score ranges from a minimum of 0 to a maximum of 30.
A lower score indicates more severe cognitive impairment (i.e., a higher score reflects better cognitive function).
|
Baseline, 3, 6, 9, 12 Months
|
|
Progression of Coronary Artery Calcification (CAC)
Periodo de tiempo: Baseline, 6, 12 Months
|
Coronary Artery Calcification (CAC) progression is assessed by measuring the change in the Agatston score using Computed Tomography (CT) scans.
The Agatston score has a minimum value of 0, with no defined maximum upper limit.
A higher score indicates a greater burden of coronary artery calcification and a higher cardiovascular risk.
|
Baseline, 6, 12 Months
|
|
All-Cause Mortality
Periodo de tiempo: Up to 12 Months
|
Number of deaths from any cause during the study period.
|
Up to 12 Months
|
|
Incidence of Major Adverse Cardiovascular Events (MACEs)
Periodo de tiempo: Up to 12 Months
|
MACEs are defined as a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death.
|
Up to 12 Months
|
|
Incidence of Adverse Events
Periodo de tiempo: Baseline, 3, 6, 9, 12 Months
|
Safety will be evaluated by monitoring and recording the incidence, severity, and relationship to the intervention of any adverse events (AEs) or serious adverse events (SAEs) throughout the study period.
|
Baseline, 3, 6, 9, 12 Months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Wenge Li, MD, China-Japan Friendship Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Procesos Patológicos
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedad crónica
- Atributos de la enfermedad
- Insuficiencia renal
- Condiciones Patológicas, Signos y Síntomas
- Insuficiencia Renal Crónica
Otros números de identificación del estudio
- 2025-KY-177-1
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre ESRD (enfermedad renal en etapa terminal)
-
Brigham and Women's HospitalTerminadoHemodiálisis Crónica (ESRD)Estados Unidos
-
Assiut UniversityDesconocidoEvaluación de la Nutrición en ESRD
-
FibroGenAstraZenecaTerminadoAnemia asociada con enfermedad renal en etapa terminal (ESRD)Estados Unidos
-
Rockwell Medical Technologies, Inc.TerminadoEnfermedad renal en etapa terminal (ESRD)Estados Unidos, Canadá
-
Charles Drew University of Medicine and ScienceNational Institutes of Health (NIH); Rockwell Medical Technologies, Inc.TerminadoEnfermedad renal en etapa terminal (ESRD)Estados Unidos
-
Merit Medical Systems, Inc.CryoLife, Inc.TerminadoEnfermedad renal en etapa terminal (ESRD)Estados Unidos
-
Hadassah Medical OrganizationDesconocido
-
Pursuit Vascular, Inc.Fresenius Medical Care North AmericaTerminadoEnfermedad renal en etapa terminal (ESRD)Estados Unidos
-
National Taiwan University HospitalDesconocido
-
Medical Components, Inc dba MedCompRetiradoEnfermedad renal en etapa terminal (ESRD)Países Bajos, Bélgica, Reino Unido
Ensayos clínicos sobre pHA130 Hemoadsorption Cartridge
-
Peking University People's HospitalReclutamientoEnfermedad renal en etapa terminal en diálisisPorcelana
-
Xinhua Hospital, Shanghai Jiao Tong University...ReclutamientoEnfermedad renal en etapa terminal en diálisisPorcelana